{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:16:40Z","timestamp":1793744200538,"version":"4.6.1"},"reference-count":130,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012866","name":"University of Calgary Faculty of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012866","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.critrevonc.2023.104041","type":"journal-article","created":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T05:19:44Z","timestamp":1685596784000},"page":"104041","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Evidence-based mechanisms of synergy with IMiD agent-based combinations in multiple myeloma"],"prefix":"10.1016","volume":"188","author":[{"given":"Paola","family":"Neri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inger","family":"Nijhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2023.104041_bib1","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.exphem.2022.07.303","article-title":"Efficacy and safety of replacing lenalidomide with pomalidomide for patients with multiple myeloma refractory to a lenalidomide-containing combination regimen","volume":"114","author":"Afari","year":"2022","journal-title":"Exp. Hematol."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104041_bib2","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/hon.3012","article-title":"Ibrutinib, lenalidomide and dexamethasone in patients with relapsed and\/or refractory multiple myeloma: phase I trial results","volume":"40","author":"Ailawadhi","year":"2022","journal-title":"Hematol. Oncol."},{"issue":"suppl 1","key":"10.1016\/j.critrevonc.2023.104041_bib3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1182\/blood-2020-137710","article-title":"Preclinical and translational support for clinical development of iberdomide in combination with proteasome inhibitors: mechanism of synergy in clinical trial CC-220-MM-001","volume":"136","author":"Amatangelo","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.critrevonc.2023.104041_bib4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2020-137667","article-title":"Preclinical and translational data support development of iberdomide in combination with CD38- and SLAMF7-directed monoclonal antibodies: evidence for rational combinations","volume":"136","author":"Amatangelo","year":"2020","journal-title":"Blood"},{"issue":"10214","key":"10.1016\/j.critrevonc.2023.104041_bib5","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.critrevonc.2023.104041_bib6","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1038\/s41375-020-0711-6","article-title":"Daratumumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study","volume":"34","author":"Bahlis","year":"2020","journal-title":"Leukemia"},{"issue":"suppl 1","key":"10.1016\/j.critrevonc.2023.104041_bib7","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/blood-2022-162440","article-title":"Efficacy and safety of elranatamab in patients with relapsed\/refractory multiple myeloma na\u00efve to B-cell maturation antigen (BCMA)-directed therapies: results from cohort a of the Magnetismm-3 study","volume":"140","author":"Bahlis","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104041_bib8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00262-014-1610-3","article-title":"Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-alpha pathways","volume":"64","author":"Balasa","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104041_bib9","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.4049\/jimmunol.173.6.3653","article-title":"LFA-1 contributes an early signal for NK cell cytotoxicity","volume":"173","author":"Barber","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2023.104041_bib10","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.3389\/fimmu.2019.01121","article-title":"Cell of origin and genetic alterations in the pathogenesis of multiple myeloma","volume":"10","author":"Barwick","year":"2019","journal-title":"Front Immunol."},{"issue":"21","key":"10.1016\/j.critrevonc.2023.104041_bib11","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1182\/blood-2015-11-682518","article-title":"Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma","volume":"127","author":"Baz","year":"2016","journal-title":"Blood"},{"issue":"10297","key":"10.1016\/j.critrevonc.2023.104041_bib12","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104041_bib13","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1182\/blood-2015-03-575365","article-title":"Promising therapies in multiple myeloma","volume":"126","author":"Bianchi","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104041_bib14","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/s41375-019-0620-8","article-title":"Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN","volume":"34","author":"Bjorklund","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2023.104041_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.66","article-title":"Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4","volume":"5","author":"Bjorklund","year":"2015","journal-title":"Blood Cancer J."},{"issue":"12","key":"10.1016\/j.critrevonc.2023.104041_bib16","doi-asserted-by":"crossref","first-page":"e602","DOI":"10.3324\/haematol.2017.186924","article-title":"Treatment optimization for multiple myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in in vitro and ex vivo models","volume":"103","author":"Borsi","year":"2018","journal-title":"Haematologica"},{"issue":"suppl 1","key":"10.1016\/j.critrevonc.2023.104041_bib17","article-title":"Single-cell characterization of the multiple myeloma (MM) immune microenvironment identifies CD27- T cells as potential source of tumor-reactive lymphocytes","volume":"134","author":"Botta","year":"2019","journal-title":"Blood"},{"issue":"suppl 15","key":"10.1016\/j.critrevonc.2023.104041_bib18","article-title":"Effect of IMiD compounds on CD38 expression on multiple myeloma cells: MOR202, a human CD38 antibody in combination with pomalidomide","volume":"33","author":"Boxhammer","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104041_bib19","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/s41375-020-0855-4","article-title":"Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab","volume":"35","author":"Casneuf","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2023.104041_bib20","unstructured":"Celgene, 2020. REVLIMID (lenalidomide): Summary of Product Characteristics."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104041_bib21","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1182\/blood-2009-03-213009","article-title":"Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma","volume":"115","author":"Chauhan","year":"2010","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.critrevonc.2023.104041_bib22","doi-asserted-by":"crossref","first-page":"5311","DOI":"10.1158\/1078-0432.CCR-11-0476","article-title":"In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells","volume":"17","author":"Chauhan","year":"2011","journal-title":"Clin. Cancer Res"},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104041_bib23","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.V87.3.1104.bloodjournal8731104","article-title":"Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-KB","volume":"87","author":"Chauhan","year":"1996","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.critrevonc.2023.104041_bib24","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/ncb0805-758","article-title":"Ubiquitin signalling in the NF-kappaB pathway","volume":"7","author":"Chen","year":"2005","journal-title":"Nat. Cell Biol."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104041_bib25","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/leu.2017.329","article-title":"Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond","volume":"32","author":"Chim","year":"2018","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/j.critrevonc.2023.104041_bib26","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1182\/bloodadvances.2020002524","article-title":"The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models","volume":"4","author":"Cho","year":"2020","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104041_bib27","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1158\/2326-6066.CIR-15-0055","article-title":"T-cell exhaustion in multiple myeloma relapse after autotransplant: optimal timing of immunotherapy","volume":"4","author":"Chung","year":"2016","journal-title":"Cancer Immunol. Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104041_bib28","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3390\/ijms22031103","article-title":"Role of Aiolos and Ikaros in the antitumor and immunomodulatory activity of IMiDs in multiple myeloma: better to lose than to find them","volume":"22","author":"Cippitelli","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104041_bib29","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3324\/haematol.2012.069328","article-title":"Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular Therapy","volume":"98","author":"Coman","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2023.104041_bib30","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.critrevonc.2017.11.016","article-title":"A question of class: treatment options for patients with relapsed and\/or refractory multiple myeloma","volume":"121","author":"Cook","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"25","key":"10.1016\/j.critrevonc.2023.104041_bib31","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma","volume":"40","author":"Costa","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2023.104041_bib32","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global burden of multiple myeloma: a systematic analysis for the Global Burden of Disease Study 2016","volume":"4","author":"Cowan","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2023.104041_bib33","volume":"Supplement 1","author":"Croft","year":"2018","journal-title":"Blood 132"},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104041_bib34","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/bjh.13780","article-title":"Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide","volume":"171","author":"Das","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2023.104041_bib35","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.3389\/fimmu.2018.03171","article-title":"Immunomodulatory drugs in the context of autologous hematopoietic stem cell transplantation associate with reduced pro-tumor T cell subsets in multiple myeloma","volume":"9","author":"Di Lullo","year":"2018","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.critrevonc.2023.104041_bib36","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/leu.2009.147","article-title":"Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"23","author":"Dimopoulos","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2023.104041_bib37","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S2152-2650(21)02320-X","article-title":"Elotuzumab plus pomalidomide\/dexamethasone for relapsed\/refractory multiple myeloma: final overall survival from the phase 2 ELOQUENT-3 trial","volume":"21","author":"Dimopoulos","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"19","key":"10.1016\/j.critrevonc.2023.104041_bib38","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N. Engl. J. Med"},{"issue":"9","key":"10.1016\/j.critrevonc.2023.104041_bib39","first-page":"91","article-title":"Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood","volume":"10","author":"Dimopoulos","year":"2020","journal-title":"Cancer J."},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104041_bib40","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104041_bib41","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.60","article-title":"Significance of the absolute lymphocyte\/monocyte ratio as a prognostic immune biomarker in newly diagnosed multiple myeloma","volume":"7","author":"Dosani","year":"2017","journal-title":"Blood Cancer J."},{"issue":"10068","key":"10.1016\/j.critrevonc.2023.104041_bib42","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104041_bib43","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41408-020-0311-8","volume":"10","author":"Durie","year":"2020","journal-title":"Blood Cancer J."},{"issue":"7","key":"10.1016\/j.critrevonc.2023.104041_bib44","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/nm.4128","article-title":"Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity","volume":"22","author":"Eichner","year":"2016","journal-title":"Nat. Med"},{"issue":"22","key":"10.1016\/j.critrevonc.2023.104041_bib45","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.critrevonc.2023.104041_bib46","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.3109\/10428194.2014.904511","article-title":"Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma","volume":"55","author":"Favaloro","year":"2014","journal-title":"Leuk. Lymphoma"},{"issue":"20","key":"10.1016\/j.critrevonc.2023.104041_bib47","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1182\/blood-2018-05-850727","article-title":"IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos","volume":"132","author":"Fedele","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104041_bib48","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/leu.2015.190","article-title":"Mitochondrial thioredoxin reductase regulates major cytotoxicity pathways of proteasome inhibitors in multiple myeloma cells","volume":"30","author":"Fink","year":"2016","journal-title":"Leukemia"},{"issue":"74","key":"10.1016\/j.critrevonc.2023.104041_bib49","doi-asserted-by":"crossref","first-page":"34009","DOI":"10.18632\/oncotarget.26131","article-title":"Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients","volume":"9","author":"Franssen","year":"2018","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104041_bib50","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2174\/156800910791054239","article-title":"Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function","volume":"10","author":"Gandhi","year":"2010","journal-title":"Curr. Cancer Drug Targets"},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104041_bib51","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.12708","article-title":"Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN)","volume":"164","author":"Gandhi","year":"2014","journal-title":"Br. J. Haematol."},{"issue":"22","key":"10.1016\/j.critrevonc.2023.104041_bib52","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.3281.3281","article-title":"Fate of Ikaros in multiple myeloma cells upon treatment with lenalidomide and proteasome inhibitor","volume":"128","author":"Ganesan","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104041_bib53","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1158\/1541-7786.MCR-19-0431","article-title":"Combination lenalidomide\/bortezomib treatment synergistically induces calpain-dependent ikaros cleavage and apoptosis in myeloma cells","volume":"18","author":"Ganesan","year":"2020","journal-title":"Mol. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104041_bib54","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s40425-018-0371-5","article-title":"Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy","volume":"6","author":"Giles","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"15","key":"10.1016\/j.critrevonc.2023.104041_bib55","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1182\/blood-2012-08-448548","article-title":"Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans","volume":"121","author":"Gorgun","year":"2013","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.critrevonc.2023.104041_bib56","article-title":"Elranatamab in combination with daratumumab for patients (pts) with relapsed\/refractory multiple myeloma (RRMM): results from the phase 3 MagnetisMM-5 study safety lead-in cohort","volume":"140","author":"Grosicki","year":"2022","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104041_bib57","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.4049\/jimmunol.1000761","article-title":"Tethering of intercellular adhesion molecule on target cells is required for LFA-1-dependent NK cell adhesion and granule polarization","volume":"185","author":"Gross","year":"2010","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.critrevonc.2023.104041_bib58","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.3324\/haematol.2020.247015","article-title":"Multiple myeloma: the (r)evolution of current therapy and a glance into future","volume":"105","author":"Gulla","year":"2020","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.critrevonc.2023.104041_bib59","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1038\/sj.leu.2402295","article-title":"Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications","volume":"15","author":"Gupta","year":"2001","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104041_bib60","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood.V91.1.3","article-title":"Multiple myeloma: increasing evidence for a multistep transformation process","volume":"91","author":"Hallek","year":"1998","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.critrevonc.2023.104041_bib61","doi-asserted-by":"crossref","first-page":"6648","DOI":"10.1021\/acs.jmedchem.9b01928","article-title":"Discovery of CRBN E3 ligase modulator CC-92480 for the treatment of relapsed and refractory multiple myeloma","volume":"63","author":"Hansen","year":"2020","journal-title":"J. Med Chem."},{"issue":"11","key":"10.1016\/j.critrevonc.2023.104041_bib62","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.3390\/cancers13112649","article-title":"Therapeutic targeting of protein disulfide isomerase PDIA1 in multiple myeloma","volume":"13","author":"Hasipek","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"19","key":"10.1016\/j.critrevonc.2023.104041_bib63","doi-asserted-by":"crossref","first-page":"16639","DOI":"10.1074\/jbc.M200360200","article-title":"NF-kappa B as a therapeutic target in multiple myeloma","volume":"277","author":"Hideshima","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.critrevonc.2023.104041_bib64","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood.V96.9.2943","article-title":"Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy","volume":"96","author":"Hideshima","year":"2000","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104041_bib65","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2147\/TCRM.S1445","article-title":"A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma","volume":"4","author":"Hideshima","year":"2008","journal-title":"Ther. Clin. Risk Manag."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104041_bib66","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s40265-017-0689-1","article-title":"Immunomodulatory drugs in multiple myeloma: mechanisms of action and clinical experience","volume":"77","author":"Holstein","year":"2017","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104041_bib67","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1182\/blood-2010-04-278432","article-title":"The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy","volume":"117","author":"Hsu","year":"2011","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.critrevonc.2023.104041_bib68","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.3109\/10428194.2014.1003057","article-title":"Absolute lymphocyte count as predictor of overall survival for patients with multiple myeloma treated with single autologous stem cell transplant","volume":"56","author":"Jimenez-Zepeda","year":"2015","journal-title":"Leuk. Lymphoma"},{"issue":"12","key":"10.1016\/j.critrevonc.2023.104041_bib69","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/ajh.22163","article-title":"Tumor-primed natural killer cells from patients with multiple myeloma lyse autologous, NK-resistant, bone marrow-derived malignant plasma cells","volume":"86","author":"Katodritou","year":"2011","journal-title":"Am. J. Hematol."},{"issue":"suppl 1","key":"10.1016\/j.critrevonc.2023.104041_bib70","article-title":"Mechanistic insights of pomalidomide activity in combination with bortezomib and dexamethasone in multiple myeloma and immune cells","volume":"132","author":"Katz","year":"2018","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.critrevonc.2023.104041_bib71","doi-asserted-by":"crossref","first-page":"22382","DOI":"10.1074\/jbc.M100938200","article-title":"Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity","volume":"276","author":"Keifer","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104041_bib72","first-page":"9450","article-title":"Potent antitumor effect of combination therapy with sub-optimal doses of Akt inhibitors and pomalidomide plus dexamethasone in multiple myeloma","volume":"15","author":"Kinoshita","year":"2018","journal-title":"Oncol. Lett."},{"issue":"9","key":"10.1016\/j.critrevonc.2023.104041_bib73","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2011-04-348292","article-title":"Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial","volume":"118","author":"Kneppers","year":"2011","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.critrevonc.2023.104041_bib74","doi-asserted-by":"crossref","first-page":"7498","DOI":"10.1158\/1078-0432.CCR-17-2027","article-title":"Monocytes and granulocytes reduce CD38 expression levels on myeloma cells in patients treated with daratumumab","volume":"23","author":"Krejcik","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"suppl 1","key":"10.1016\/j.critrevonc.2023.104041_bib75","volume":"140","author":"Krishnan","year":"2022","journal-title":"Blood"},{"issue":"6168","key":"10.1016\/j.critrevonc.2023.104041_bib76","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kronke","year":"2014","journal-title":"Science"},{"issue":"suppl 1","key":"10.1016\/j.critrevonc.2023.104041_bib77","article-title":"MagnetisMM-4: an open label, phase 1b\/2 umbrella study of elranatamab in combination with other anti-cancer treatments for patients with multiple myeloma","volume":"140","author":"Landgren","year":"2022","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.critrevonc.2023.104041_bib78","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1182\/blood.2020009507","article-title":"Dose\/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma","volume":"137","author":"Larocca","year":"2021","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.critrevonc.2023.104041_bib79","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2023.104041_bib80","article-title":"Iberdomide (IBER) in combination with dexamethasone (DEX) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): Results from the dose-expansion phase of the CC-220-MM-001 trial","volume":"138","author":"Lonial","year":"2021","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.critrevonc.2023.104041_bib81","doi-asserted-by":"crossref","first-page":"e822","DOI":"10.1016\/S2352-3026(22)00290-3","article-title":"Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1\/2 trial","volume":"9","author":"Lonial","year":"2022","journal-title":"Lancet Haematol."},{"issue":"Suppl_1","key":"10.1016\/j.critrevonc.2023.104041_bib82","article-title":"CC-92480 is a novel cereblon E3 ligase modulator with enhanced tumoricidal and immunomodulatory activity against sensitive and resistant multiple myeloma cells","volume":"134","author":"Lopez-Girona","year":"2019","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.critrevonc.2023.104041_bib83","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/leu.2012.119","article-title":"Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide","volume":"26","author":"Lopez-Girona","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2023.104041_bib84","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.3389\/fimmu.2018.01328","article-title":"Monocyte-derived dendritic cells differentiated in the presence of lenalidomide display a semi-mature phenotype, enhanced phagocytic capacity, and Th1 polarization capability","volume":"9","author":"Lopez-Relano","year":"2018","journal-title":"Front Immunol."},{"issue":"6168","key":"10.1016\/j.critrevonc.2023.104041_bib85","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104041_bib86","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/hon.3035","article-title":"Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: Italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials","volume":"40","author":"Martino","year":"2022","journal-title":"Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104041_bib87","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1021\/acs.jmedchem.6b01921","article-title":"A cereblon modulator (CC-220) with improved degradation of Ikaros and Aiolos","volume":"61","author":"Matyskiela","year":"2018","journal-title":"J. Med Chem."},{"issue":"12","key":"10.1016\/j.critrevonc.2023.104041_bib88","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1182\/blood.V99.12.4525","article-title":"Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications","volume":"99","author":"Mitsiades","year":"2002","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.critrevonc.2023.104041_bib89","article-title":"TIG-007: study of EOS884448\/GSK4428859A alone, and in combination with iberdomide with or without dexamethasone, in participants with relapsed or refractory multiple myeloma","volume":"138","author":"Moreau","year":"2021","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.critrevonc.2023.104041_bib90","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"suppl 1","key":"10.1016\/j.critrevonc.2023.104041_bib91","article-title":"Updated results from MajesTEC-1: phase 1\/2 study of teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in relapsed\/refractory multiple myeloma","volume":"138","author":"Moreau","year":"2021","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.critrevonc.2023.104041_bib92","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Eng. J. Med."},{"key":"10.1016\/j.critrevonc.2023.104041_bib93","doi-asserted-by":"crossref","first-page":"1852517","DOI":"10.1155\/2017\/1852517","article-title":"Inflammatory and anti-inflammatory equilibrium, proliferative and antiproliferative balance: the role of cytokines in multiple myeloma","volume":"2017","author":"Musolino","year":"2017","journal-title":"Mediat. Inflamm."},{"issue":"suppl 1","key":"10.1016\/j.critrevonc.2023.104041_bib94","article-title":"Immunome single cell profiling reveals T cell exhaustion with upregulation of checkpoint inhibitors LAG3 and TIGIT on marrow infiltrating T lymphocytes in daratumumab and IMiDs resistant patients","volume":"132","author":"Neri","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.critrevonc.2023.104041_bib95","article-title":"Transcriptional plasticity compensates for Ikaros and Aiolos proteasomal degradation and mediates resistance to IMiDs in multiple myeloma (MM)","volume":"130","author":"Neri","year":"2017","journal-title":"Blood"},{"issue":"58","key":"10.1016\/j.critrevonc.2023.104041_bib96","doi-asserted-by":"crossref","first-page":"98200","DOI":"10.18632\/oncotarget.21516","article-title":"Lenalidomide overcomes the immunosuppression of regulatory CD8(+)CD28(-) T-cells","volume":"8","author":"Neuber","year":"2017","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.critrevonc.2023.104041_bib97","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","article-title":"CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.critrevonc.2023.104041_bib98","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1182\/blood-2016-07-729236","article-title":"Phase 1\/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.critrevonc.2023.104041_bib99","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1158\/1078-0432.CCR-14-1813","article-title":"Preclinical evidence for the therapeutic potential of CD38-targeted immuno-chemotherapy in multiple myeloma patients refractory to lenalidomide and bortezomib","volume":"21","author":"Nijhof","year":"2015","journal-title":"Clin. Cancer Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104041_bib100","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1007","article-title":"Endoplasmic reticulum stress in the development of multiple myeloma and drug resistance","volume":"7","author":"Nikesitch","year":"2018","journal-title":"Clin. Transl. Immunol."},{"issue":"7","key":"10.1016\/j.critrevonc.2023.104041_bib101","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1158\/1078-0432.CCR-21-3420","article-title":"Safety and efficacy of combination maintenance therapy with ixazomib and lenalidomide in patients with posttransplant myeloma","volume":"28","author":"Patel","year":"2022","journal-title":"Clin. Cancer Res"},{"issue":"22","key":"10.1016\/j.critrevonc.2023.104041_bib102","doi-asserted-by":"crossref","first-page":"5895","DOI":"10.1158\/1078-0432.CCR-20-1781","article-title":"Immunomodulation in pomalidomide, dexamethasone, and daratumumab-treated patients with relapsed\/refractory multiple myeloma","volume":"26","author":"Pierceall","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2023.104041_bib103","article-title":"P06: updated results from the phase 1\/2 MAJESTEC-1 study of teclistamab, a B-cell maturation antigen X CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma","volume":"6 suppl","author":"Popat","year":"2022","journal-title":"Hemasphere"},{"key":"10.1016\/j.critrevonc.2023.104041_bib104","article-title":"Modulation of NK, T, & B cell-sub-populations by pomalidomide predicts favorable progression-free survival: results from a large randomized clinical trial in relapsed\/refractory myeloma","volume":"19","author":"Prabhala","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk"},{"issue":"suppl 1","key":"10.1016\/j.critrevonc.2023.104041_bib105","article-title":"Immune profile of patients (pts) with relapsed and\/or refractory multiple myeloma (RRMM) treated with pomalidomide (POM) + low-dose dexamethasone (LoDEX) + daratumumab (DARA) in the second line immediately after lenalidomide (LEN)","volume":"130","author":"Qian","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.critrevonc.2023.104041_bib106","article-title":"Elranatamab, a BCMA targeted T-cell engaging bispecific antibody, induces durable clinical and molecular responses for patients with relapsed or refractory multiple myeloma","volume":"140","author":"Raje","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104041_bib107","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol."},{"issue":"suppl 1","key":"10.1016\/j.critrevonc.2023.104041_bib108","article-title":"Investigating mechanisms of elotuzumab and lenalidomide therapy in multiple myeloma","volume":"3","author":"Richardson","year":"2019","journal-title":"Hemasphere"},{"key":"10.1016\/j.critrevonc.2023.104041_bib109","first-page":"781","article-title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial","volume":"20","author":"Richardson","year":"2019"},{"issue":"suppl 15","key":"10.1016\/j.critrevonc.2023.104041_bib110","article-title":"First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"38","author":"Richardson","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104041_bib111","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/198539","article-title":"Immunological dysregulation in multiple myeloma microenvironment","volume":"2014","author":"Romano","year":"2014","journal-title":"Biomed. Res Int."},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104041_bib112","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/bjh.13905","article-title":"Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma","volume":"172","author":"Rychak","year":"2016","journal-title":"Br. J. Haematol."},{"issue":"11","key":"10.1016\/j.critrevonc.2023.104041_bib113","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"San Miguel","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2023.104041_bib114","doi-asserted-by":"crossref","DOI":"10.1177\/2040620721989585","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies","volume":"12","author":"Sanchez","year":"2021","journal-title":"Ther. Adv. Hematol."},{"issue":"8","key":"10.1016\/j.critrevonc.2023.104041_bib115","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1182\/blood-2016-09-738872","article-title":"Multiple myeloma cells' capacity to decompose H2O2 determines lenalidomide sensitivity","volume":"129","author":"Sebastian","year":"2017","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.critrevonc.2023.104041_bib116","first-page":"e315","article-title":"Proteasome inhibitors block Ikaros degradation by lenalidomide in multiple myeloma","volume":"100","author":"Shi","year":"2015","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.critrevonc.2023.104041_bib117","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1200\/JCO.2017.76.5032","article-title":"Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"36","author":"Siegel","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2023.104041_bib118","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1038\/s41375-022-01691-1","article-title":"Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma","volume":"36","author":"Slade","year":"2022","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.critrevonc.2023.104041_bib119","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000786","article-title":"Carfilzomib, pomalidomide, and dexamethasone as second-line therapy for lenalidomide-refractory multiple myeloma","volume":"6","author":"Sonneveld","year":"2022","journal-title":"Hemasphere"},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104041_bib120","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000350","article-title":"Beyond DNA damage: exploring the immunomodulatory effects of cyclophosphamide in multiple myeloma","volume":"4","author":"Swan","year":"2020","journal-title":"Hemasphere"},{"issue":"15","key":"10.1016\/j.critrevonc.2023.104041_bib121","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.18632\/oncotarget.27973","article-title":"Developing next generation immunomodulatory drugs and their combinations in multiple myeloma","volume":"12","author":"Thakurta","year":"2021","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104041_bib122","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","article-title":"CD38 antibodies in multiple myeloma: back to the future","volume":"131","author":"van de Donk","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.critrevonc.2023.104041_bib123","article-title":"First results of iberdomide (IBER; CC-220) in combination with dexamethasone (DEX) and daratumumab (DARA) or bortezomib (BORT) in patients with relapsed\/refractory multiple myeloma (RRMM)","author":"van de Donk","year":"2020","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104041_bib124","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3324\/haematol.2010.030759","article-title":"Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab","volume":"96","author":"van der Veer","year":"2011","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104041_bib125","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1158\/1535-7163.MCT-12-0782","article-title":"Endoplasmic reticulum stress and the unfolded protein response: targeting the Achilles heel of multiple myeloma","volume":"12","author":"Vincenz","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2023.104041_bib126","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.blre.2018.11.003","article-title":"The impact of NF-\u03baB signaling on pathogenesis and current treatment strategies in multiple myeloma","volume":"34","author":"Vr\u00e1bel","year":"2019","journal-title":"Blood Rev."},{"key":"10.1016\/j.critrevonc.2023.104041_bib127","article-title":"Harnessing the immune system against multiple myeloma: challenges and opportunities","volume":"10","author":"Yamamoto","year":"2020","journal-title":"Front Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104041_bib128","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","article-title":"BCMA-targeted immunotherapy for multiple myeloma","volume":"13","author":"Yu","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"suppl 1","key":"10.1016\/j.critrevonc.2023.104041_bib129","article-title":"MajesTEC-4 (EMN30): a phase 3 trial of teclistamab + lenalidomide versus lenalidomide alone as maintenance therapy following autologous stem cell transplantation in patients with newly diagnosed multiple myeloma","volume":"140","author":"Zamagni","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104041_bib130","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1080\/16078454.2022.2121900","article-title":"Efficacy of maintenance treatment in patients with multiple myeloma: a systematic review and network meta-analysis","volume":"27","author":"Zhi","year":"2022","journal-title":"Hematology"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842823001294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842823001294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:47:46Z","timestamp":1760903266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842823001294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":130,"alternative-id":["S1040842823001294"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104041","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evidence-based mechanisms of synergy with IMiD agent-based combinations in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104041"}}